



(11) **EP 3 323 815 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**C07D 277/28** <sup>(2006.01)</sup> **C07D 417/04** <sup>(2006.01)</sup>  
**C07D 417/12** <sup>(2006.01)</sup> **C07D 417/14** <sup>(2006.01)</sup>  
**A61K 31/425** <sup>(2006.01)</sup> **A61P 35/00** <sup>(2006.01)</sup>

(48) Corrigendum issued on:  
**30.12.2020 Bulletin 2020/53**

(45) Date of publication and mention  
of the grant of the patent:  
**07.10.2020 Bulletin 2020/41**

(21) Application number: **17191765.1**

(22) Date of filing: **27.06.2007**

---

(54) **HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE**  
HUMANE PROTEINTYROSINPHOSPHATASEINHIBITOREN UND IHRE VERWENDUNG  
INHIBITEURS DE PROTÉINES TYROSINE-PHOSPHATASES HUMAINES ET LEUR UTILISATION

---

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE  
SI SK TR**

(30) Priority: **27.06.2006 US 816730 P**

(43) Date of publication of application:  
**23.05.2018 Bulletin 2018/21**

(60) Divisional application:  
**20200440.4**

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
**12196174.2 / 2 592 072**  
**07809907.4 / 2 041 102**

(73) Proprietor: **Aerpio Pharmaceuticals, Inc.**  
**Cincinnati, OH 45242 (US)**

(72) Inventors:  
• **GRAY, Jeffrey Lyle**  
**Loveland OH Ohio 45140 (US)**  
• **CLARK, Cynthia Monesa**  
**Concord MA Massachusetts 01742 (US)**  
• **AMARASINGHE, Kande K.D.**  
**Ellicott City MD Maryland 21042 (US)**  
• **MAIER, Matthew Brian**  
**Chesapeake, VA 23321 (US)**  
• **NICHOLS, Ryan**  
**Cincinnati OH Ohio 45212 (US)**

(74) Representative: **Avidity IP**  
**Broers Building**  
**Hauser Forum**  
**21 JJ Thomson Avenue**  
**Cambridge CB3 0FA (GB)**

(56) References cited:  
**US-A1- 2004 167 183 US-B1- 6 596 772**

---

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

---

**EP 3 323 815 B8**